Teva Pharmaceutical Industries Limited (NYSE:TEVA)
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s Financial Overview
Teva Pharmaceutical Industries Limited (NYSE) surged 1.59% yesterday to close its trading session at $19.12. The company has 1 year Price Target of $22.47. Teva Pharmaceutical Industries Limited has 52-Week high of $25.96 and 52-Week Low of $14.59. The stock touched its 52-Week High on 25.96 and 52-Week Low on 14.59. The stock traded with the volume of 11.44 Million shares yesterday. The firm shows the market capitalization of $21.27 Billion.
Teva Pharmaceutical Industries Limited (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.68/share against the analyst consensus estimate of $0.54/share. The difference between the actual and expected EPS is $0.14 a share with a surprise factor of 25.9%.
The firm is trading with SMA20 of -0.4 Percent, SMA50 of 3.56 Percent and SMA200 of -10.37 percent. Teva Pharmaceutical Industries Limited has P/S value of 1.08 while its P/B value stands at 1.4. Similarly, the company has Return on Assets of -16.3 percent, Return on Equity of -78 percent and Return on Investment of -36 Percent. The company shows Gross Margin and Operating Margin of 45.4 percent and -59 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 17 analysts offering 12-month price forecasts for Teva Pharmaceutical Industries Ltd have a median target of 24.00, with a high estimate of 30.00 and a low estimate of 16.00. The median estimate represents a +25.52% increase from the last price of 19.12.
Teva Pharmaceutical Industries Limited is expected* to report earnings on 02/13/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.53. The reported EPS for the same quarter last year was $0.91.
Banco Bilbao Viscaya Argentaria S.A. (NYSE:BBVA)
Banco Bilbao Vizcaya is engaged in a wide variety of banking, financial and related activities in Spain.
Banco Bilbao Viscaya Argentaria S.A. (NYSE:BBVA)’s Financial Outlook
The 25 analysts offering 12-month price forecasts for Banco Bilbao Vizcaya Argentaria S.A. have a median target of 6.96, with a high estimate of 8.65 and a low estimate of 5.68. The median estimate represents a +17.89% increase from the last price of 5.90.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, Banco Bilbao Viscaya Argentaria S.A. has a Consensus Recommendation of 2.75. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 2.08% and closed its last trading session at $5.9. The company has the market capitalization of $39.12 Billion. The stock has 52-week high of $8.82 and 52-Week low of $4.99. The firm touched its 52-Week high on 8.82 and 52-Week low on 4.99. The company has volume of 6.35 Million shares. The company has a total of 6.63 Billion shares outstanding.
The company has YTD performance of 11.53 percent. Beta for Banco Bilbao Viscaya Argentaria S.A. stands at 0.99 while its ATR (average true range) is 0.12. The company has Weekly Volatility of 1.28%% and Monthly Volatility of 1.60%%.
Banco Bilbao Viscaya Argentaria S.A. has distance from 20-day Simple Moving Average (SMA20) of -0.39%, Distance from 50-Day Simple Moving Average of 5.32 percent and Distance from 200-Day Simple Moving Average of -7.8%.
The Company currently has ROA (Return on Assets) of 0.5 percent, Return on Equity (ROE) of 7.8 Percent and Return on Investment (ROI) of 11.1% with Gross margin of 0 percent and Operating & Profit margin of 54% and 13.5% respectively.